Mesoblast Ltd
RYONCIL
Steroid-Refractory Acute Graft Versus Host Disease (SR-aGvHD)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews RYONCIL for Steroid-Refractory Acute Graft Versus Host Disease (SR-aGvHD) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 12h ago
“Following FDA meeting Following central IRB approval in March, site initiation and patient enrollment to commence”